Adoptive cellular therapy (ACT), which includes tumor-infiltrating lymphocyte (TIL) therapy; T-cell receptor (TCR) therapy; and Chimeric Antigen Receptor (CAR) T-cell therapy, is at a critical juncture. While some successes have been realized, broader life-saving successes have often been stymied by research and technology shortcomings. Fortunately, recent genomic, immunologic, and cell manufacturing advances have shown promise in overcoming the obstacles that have impeded greater ACT progress. Download this infographic now to learn more about how ACTs work, what’s in the pipeline, and some of the success stories having a big impact on cancer patients.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.